News - Velcade, Oncology


Current filters:


Popular Filters

ASCO 2014: Takeda, Roche and Celgene present results

ASCO 2014: Takeda, Roche and Celgene present results


A host of results have been presented by global pharma majors at the 2014 Annual Meeting of the American…

AbraxaneCelgeneOncologyPharmaceuticalResearchRocheTakeda PharmaceuticalsUSAVelcade

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta


People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma


In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma


In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

EU backs wider use of Velcade


The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma


Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers


A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Multiple myeloma drug market forecast to reach $7.2 billion in 2021


The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

First-line multiple myeloma patient share in Europe is variable by country


Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

Johnson & Johnson pulls EU submission for Velcade use in NHL


The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

5.6% annual growth forecast for multiple myeloma drug market to 2020


Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and…

CelgeneGlobalJanssen-CilagMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top